Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival—a substudy of the MIMOSA trial

PARP inhibitors in ovarian cancer: Current status and future promise

(2014) Joyce F. Liu et al.   GYNECOLOGIC ONCOLOGY

Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study

(2013) Paul Sabbatini et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular/Genetic Therapies in Ovarian Cancer

(2012) ANGELA J. ZIEBARTH et al.   CLINICAL OBSTETRICS AND GYNECOLOGY

Contemporary use of bevacizumab in ovarian cancer

(2012) Takahito M Miyake et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients

(2011) Francesco Legge et al.   BMC CANCER

Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies

(2009) M. Campoli et al.   CLINICAL CANCER RESEARCH

Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature

(2009) Digant Gupta et al.   Journal of Ovarian Research

The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer

(2008) Patricia Braly et al.   JOURNAL OF IMMUNOTHERAPY